Skip to main content
OpenTrials
Completed

NCT Number: NCT00769236

Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Crohn's Disease Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laboratoire d'Immunologie - Hopital de la Conception

Marseille, 13005, France

About this study

Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients reached by disease of crohn
  • patients reached by hemorrhagic first side-colitis

Exclusion criteria

  • Forms ileales or ano-périneales pure of disease of crohn
  • indefinite colitis

Treatment and study plan

Blood sampling and biopsy

Other

Biopsy and blood : Research for various antibodies

Biopsy and blood sampling

Other

Biopsy and blood : research for various antibodies

Primary outcomes

  1. Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum

    Time frame: 24 months

Secondary outcomes

  1. Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Oct 9, 2008
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.